NCI Cancer Bulletin
A Trusted Source for Cancer Research News
November 18, 2008 • Volume 5 / Number 23 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Bulletin Home

Featured Article
NCI Technology Research Facility Gets Off the Ground

Cancer Research Highlights
Bevacizumab May Increase Blood Clot Risk

Number of Adult U.S. Smokers Drops, But So Do Quit Attempts

PAX2 Protein Mediates Effect of Tamoxifen in Breast Cancer

Burden of Cervical Cancer Prior to HPV Vaccine Assessed

Director's Update
Building an Advanced Technology Research Initiative

FDA Update
New Option Approved for Indolent NHL

Special Report
A Cancer Genome is Sequenced, Revealing Rare Mutations

Featured Clinical Trial
New Drug for Patients with Advanced Thyroid Cancer

Special Issue on Cancer Imaging

Cancer Disparities: A Biological and Psychosocial Perspective

Also in the Journals

Community Update
Researchers Consider "NCI Translates" Approach

NCI Advisors Approve Major Cancer Research Initiatives

Understanding NCI Teleconference: Translational Research Working Group

In Memoriam
Dr. Ronald M. Davis

Cancer Center Profile
Memorial Sloan-Kettering Cancer Center

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Cancer Center Profile Cancer Center Profile

Memorial Sloan-Kettering Cancer Center
President: Dr. Harold Varmus • 1275 York Avenue, New York, NY 10065 • Phone: 212-639-2000 • Web site:

A photo of the recently opened Zuckerman Research Center at Memorial Sloan-Kettering Cancer Center.Background
Founded in 1884, Memorial Sloan-Kettering Cancer Center (MSKCC) is the world's oldest and largest private cancer center, with more than a century devoted to patient care and innovative research, making significant contributions to better understand, diagnose, and treat cancer. MSKCC is one of only 41 NCI-designated Comprehensive Cancer Centers and it has more than 10,000 employees. In 2007, approximately 21,870 patients were admitted to Memorial Hospital, and approximately 443,830 outpatient visits were accommodated at its Manhattan and regional facilities combined.

Patient Care
MSKCC's experts have established standards of care and treatment protocols for each type and stage of cancer. Its physicians have an extraordinary depth and breadth of experience in diagnosing and treating all forms of the disease, from the most common to the very rare. Each year, they treat more than 400 different subtypes of cancer. This level of specialization can have an often dramatic effect on patients' chances for a cure or control of their disease.

MSKCC offers a full range of programs to help patients and families throughout all phases of treatment, including support groups, genetic counseling, help managing cancer pain and symptoms, rehabilitation, integrative medicine services, and assistance in navigating life after treatment.

MSKCC's physicians and scientists have pioneered many novel therapeutic regimens that have made possible the remarkable advances in cancer treatment. Physicians at MSKCC are currently leading approximately 500 clinical trials for pediatric and adult cancer patients.

The Sloan-Kettering Institute (SKI) maintains one of the world's most dynamic programs of cancer research dedicated to understanding the biology of cancer through programs in cancer biology and genetics, cell biology, computational biology, developmental biology, immunology, molecular biology, molecular pharmacology and chemistry, and structural biology. The SKI research staff includes more than 90 laboratory investigators, 404 research fellows, and 150 graduate students (both Ph.D. and M.D./Ph.D. candidates). The institute boasts nine National Academy of Sciences members and seven Howard Hughes Medical Institute investigators.

In recent years, MSKCC has undergone a major expansion, with new construction and renovations designed to meet the growing needs of both its patients and its scientific initiatives. The Center's newly opened Zuckerman Research Center has more than 300,000 square feet of laboratory space and houses many cancer research programs and laboratories. MSKCC has also developed a network of community-based, state-of-the-art outpatient cancer treatment facilities that bring the Center's expert care closer to patients living throughout its geographic region. MSKCC's new Breast and Imaging Center, which is currently under construction, will be ready for occupancy in 2009. The 16-story facility will accommodate the increasing number of breast cancer patients who come to MSKCC for treatment while also expanding services for cancer screening and diagnostic services. In 2006, MSKCC opened a new 72,000-square-foot surgical center that includes 21 state-of-the-art operating rooms, all of which are equipped for both minimally invasive and more traditional open surgery.

An exciting new dimension to MSKCC is the recent establishment of the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences. The novel program, which offers a Ph.D. degree in cancer biology, trains gifted young laboratory scientists to work in research areas directly related to cancer and other human diseases.  

< Previous Section

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health